Genistein in Treating Patients With Prostate Cancer

Inclusion Criteria

• •Inclusion
• •Participants must have a pathologic diagnosis of prostate cancer within the past 6 months, have clinical stage T1-3 disease, PSA \>= 10, Gleason score \>= 8, and have elected to undergo radical prostatectomy; those found to have detectable circulating prostate cancer cells in the blood as detected by qRT-PCR for PSA will be eligible to proceed onto the treatment phase of the protocol; pathology slides used for diagnosis will be submitted to the SPORE tissue pathology core for review
• •ECOG performance status 0-1
• •Hemoglobin \> 9.0gm/dl
• •Platelets \>= 100 K/uL
• •ANC \> 1000/uL
• •AST (SGOT)/ALT (SGPT) \< 3X upper limit of normal
• •Creatinine \< 2.0 mg/dl
• •Total bilirubin \< 2 mg/dl (Note: Subjects with a higher level of bilirubin due to a familial defect in bilirubin metabolism will be considered on an individual basis)
• •Participants must agree not to take soy supplements
• •Ability to understand and the willingness to sign a written informed consent document
• •Willingness to take study agent for at least 2 weeks prior to radical prostatectomy
• •Exclusion
• •History of venous thrombosis within past year
• •Participants must not be receiving active therapy for neoplastic disorders (including hormone or radiation therapy for prostate cancer)
• •Participants may not be receiving any other investigational agents
• •Known soy intolerance
• •Medical conditions that, in the opinion of the investigators, would jeopardize either the patient or the integrity of the data obtained